Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

Novogen Limited's subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL), has

made the following announcement:

SYDNEY, Australia and NEW CANAAN, Conn., Aug. 27 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL) today announced enrolment of the first patient in Europe in the Phase III Ovature clinical trial of phenoxodiol in women with advanced ovarian cancer resistant or refractory to platinum-based drugs.

The first patient to commence on the study at an Ovature site in the EU has been enrolled at the Catholic University of Leuven, Belgium, under the direction of Professor Ignace Vergote, Head of Gynaecologic Oncology.

"We are hopeful that a positive outcome of this multi-centre study will be a significant medical advance for thousands of women with late stage ovarian cancer whose tumours have become insensitive to the existing chemotherapeutic drugs," Professor Vergote said.

"As one of Europe's largest cancer institutions, it is important for us to be a part of these worldwide studies. It is important that we continue to develop new ovarian cancer treatments. It is only through constant research that we will learn how to battle this deadly disease effectively," said Professor Vergote.

The Catholic University of Leuven is one of 26 sites in UK and Europe which will be recruiting patients into this major multi-centre multinational ovarian cancer study to determine the safety and effectiveness of the drug phenoxodiol, w
'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 ... of the "Global Electrophysiology Ablation Catheters Market ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ... remove or destroy faulty electrical pathways from sections ... (also known as cardiac arrhythmias). Cardiac arrhythmias can ...
(Date:7/23/2014)... , July 23, 2014  Nonin Medical, Inc., the ... noninvasive medical monitoring, announced today that Mark VanderWerf ... been elected Chairman of the American Telemedicine Association,s (ATA) ... Directors. The ATA is the leading international ... medical technologies. The ATA and its diverse membership work ...
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
Breaking Medicine Technology:Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5
(Date:7/23/2014)... 2014 A Forever Recovery, an open-ended ... to a great start and gives them a solid ... a new Internet Addiction section of its website at ... learn that Internet addiction is not just as legitimate ... that it’s trapping more and more victims each year ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Adipic ... which is mainly a high-performance plastic, often referred ... range of materials, depending on the monomers employed. ... the automotive industry and the increasing number of ... adipic acid market share, followed by Europe and ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... For critically ill patients arriving at the emergency ... sedation and amnesia for rapid, life-saving intubation, despite ... The results of a systematic review of ... regard as a "wonder drug" are published online ... The Effect of Ketamine on Intracranial and Cerebral ...
(Date:7/23/2014)... July 23, 2014 SafeUseNow? ... intervention program developed by Principled Strategies , ... HealthPlan of California . Utilizing SafeUseNow’s patent-pending risk ... risk of misusing and abusing controlled substance drugs, ... addiction among its members. , The agreement with ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... Ind., Nov. 21 Symmetry Medical Inc. (NYSE: SMA ... device industry and other medical markets, announced today that Brian S. ... Vice President and Chief Financial Officer, are scheduled to present at ... York Palace Hotel on Wednesday, December 3, 2008 at 12:30 p.m. ...
... smoking will receive big prizes during a special on-ice presentation ... Energy Center. The winners,were participants in The QuitCash Challenge, a ... The grand prize winner will ... cards from Gander Mountain. , ...
... study suggests , , FRIDAY, Nov. 21 (HealthDay News) -- The ... of asthma, new research suggests. , Babies born in autumn -- ... have almost a 30 percent increased risk of asthma compared to ... in the first December issue of the American Journal of ...
... Just three days after the,JUPITER trial results were presented ... by the New England Journal of Medicine, an,AlphaDetail survey ... anticipate a 14% increase in the use of drug ... risk patients. , ...
... travel nationwide to,ten top locations for Indoor Cycling / ... of innovative cycling training DVDs. The DVDs utilize,first-person ... selectable vocal coaching from industry experts. Sally Edwards,Ironman ... Matty Reed, US,triathlete champion and Olympian are just a ...
... Draeger Safety, Inc., located in,Pittsburgh PA, and ... products,provider, is countering what it believes are unsubstantiated ... of a patent,infringement on the popular Draeger PSS7000 ... Draeger has a ...
Cached Medicine News:Health News:Lucky Quitters to Receive Big Money in Stop-Smoking Contest 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Physicians Anticipate Higher Prescribing Based on JUPITER Study 2Health News:Global Ride Tours Best 12 Cities for SPINNING(R) or Indoor Cycling 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
5.5 pointed curved blade. Octagonal handle....
3 mm curved blade. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
Medicine Products: